Trial reportInternational journal of molecular sciences2019
Expression of Longevity Genes Induced by a Low-Dose Fluvastatin and Valsartan Combination with the Potential to Prevent/Treat "Aging-Related Disorders".
Trial report in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 24 citations in OpenAlex.
- Antiaging Properties of the Klotho Protein.Cells · 2026Review
- Reduced serum Klotho in chronic schizophrenia: diagnostic value and association with cognitive impairment.Frontiers in psychiatry · 2026Article
- The Anti-Inflammatory Actions of Soluble Klotho in Brain Aging and Its Main Associated Diseases.International journal of molecular sciences · 2025Review
- The Association Between Weight-Adjusted-Waist Index and S-Klotho Levels in Adults: NHANES 2007-2016.Food science & nutrition · 2025Article
- Senolytics: charting a new course or enhancing existing anti-tumor therapies?Cellular oncology (Dordrecht, Netherlands) · 2025Review
- The effect of bempedoic acid on histopathologic changes associated with natural aging in rat lungs.BMC pulmonary medicine · 2025Article
- Relationship between uric acid to high-density cholesterol ratio (UHR) and circulating α-klotho: evidence from NHANES 2007-2016.Lipids in health and disease · 2024Article
- Sacubitril/valsartan ameliorates tubulointerstitial fibrosis by restoring mitochondrial homeostasis in diabetic kidney disease.Diabetology & metabolic syndrome · 2024Article
- Klotho: a potential therapeutic target in aging and neurodegeneration beyond chronic kidney disease-a comprehensive review from the ERA CKD-MBD working group.Clinical kidney journal · 2024Article
- The causal effects of intelligence and fluid intelligence on Parkinson's disease: a Mendelian randomization study.Frontiers in aging neuroscience · 2024Article
- Drugs against metabolic diseases as potential senotherapeutics for aging-related respiratory diseases.Frontiers in endocrinology · 2023Review
- Klotho's impact on diabetic nephropathy and its emerging connection to diabetic retinopathy.Frontiers in endocrinology · 2023Review
- Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations.Frontiers in aging · 2022Review
- Treating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs.International journal of molecular sciences · 2021Review
- Serum sirtuin 1 is independently associated with intact PTH among patients with chronic kidney disease.Clinical interventions in aging · 2021Article
- Treating Senescence like Cancer: Novel Perspectives in Senotherapy of Chronic Diseases.International journal of molecular sciences · 2020Review
- Association between Nrf2 and CDKN2A expression in patients with end-stage renal disease: a pilot study.Aging · 2020Article
- PTSD and the klotho longevity gene: Evaluation of longitudinal effects on inflammation via DNA methylation.Psychoneuroendocrinology · 2020Article
- Histone Deacetylase SIRT1, Smooth Muscle Cell Function, and Vascular Diseases.Frontiers in pharmacology · 2020Review
- Aging and Age-related Disorders: From Molecular Mechanisms to Therapies.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of aging-related disorders may be decreased through strategies influencing the expression of longevity genes. Although numerous approaches have been suggested, no effective, safe, and easily applicable approach is yet available. Efficacy of low-dose fluvastatin and valsartan, separately or in combination, on the expression of the longevity genes in middle-aged males, was assessed. Stored blood samples from 130 apparently healthy middle-aged males treated with fluvastatin (10 mg daily), valsartan (20 mg daily), fluvastatin-valsartan combination (10 and 20 mg, respectively), and placebo (control) were analyzed. They were taken before and after 30 days of treatment and, additionally, five months after treatment discontinuation. The expression of the following longevity genes was assessed:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.